Drug intelligence / Profile preview

cicloprofen

Development stage
Unknown
Lead developer
Bristol Myers Squibb
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

Cicloprofen is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivative class, chemically identified as a fluorene derivative. It functions primarily as an inhibitor of the cyclooxygenase (COX) enzymes, thereby blocking the synthesis of prostaglandins that mediate pain, inflammation, and fever. Historically developed by Squibb (as SQ 20824) for the treatment of inflammatory conditions such as rheumatoid arthritis and osteoarthritis, its clinical use has been largely superseded by other NSAIDs. In recent clinical research contexts, particularly in China, it has been investigated as an adjunct analgesic in multimodal anesthesia regimens. For instance, it has been evaluated alongside agents like oliceridine, alfentanil, and dexmedetomidine to provide perioperative analgesia and potentially mitigate adverse events such as respiratory depression and hemodynamic instability during procedural sedation for gastrointestinal endoscopy.

Other names
cycloprofen2-(9H-fluoren-2-yl)propanoic acid2-(2-fluorenyl)propionic acid
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on cicloprofen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cicloprofen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call